# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-25T16:20:10.098821

---

**Idea Fidelity**  
*Not applicable (no manifest provided).*

---

**Summary**  
The paper leverages pre-1988 triplicate prescription programs as an instrument for oxycodone supply to estimate the causal impact of pharmaceutical opioid exposure on downstream Medicaid medication-assisted treatment (MAT) demand, using DEA ARCOS shipment data (2006–2012) and T-MSIS Medicaid claims (2018–2024). The first-stage relationship is strong, showing roughly 44% fewer oxycodone pills per capita in triplicate states, and the IV estimates imply an elasticity of MAT claims to oxycodone supply close to unity, though imprecisely estimated. The proposed exclusion restriction is supported by a placebo showing no effect on non-opioid substance use disorder treatment.

---

**Essential Points**

1. **Temporal gap and monotonicity assumptions need elaboration.** The identifying variation relies on a policy adopted decades before the outcome window, mediated through Purdue’s marketing strategy in the 2000s. The paper should more thoroughly justify (perhaps with historical evidence or suggestive data) why there is no other contemporaneous channel linking triplicate status to late-2010s Medicaid treatment, and why the effect is monotonic (i.e., no triplicate state that would have had higher supply absent the program). In particular, the exclusion restriction may be violated if triplicate states adopted subsequent opioid-related policies (PDMPs, prescribing limits, Medicaid expansions) that themselves influence MAT demand today. Some discussion or data showing these policies do not systematically differ by triplicate status is necessary.

2. **Cross-sectional IV inference on 51 observations is fragile and the weak-instrument diagnostics are incomplete.** The main IV elasticity is imprecise, and the first-stage F with controls drops to 5.7, while the Anderson–Rubin test yields a high p-value, suggesting weak identification. The paper should report the Kleibergen–Paap statistic or other weak-instrument robust confidence intervals, and discuss whether the estimated effect is driven by a few influential states (particularly Illinois and Idaho, which make the coefficient near zero when dropped). Without this, readers cannot assess whether the point estimate is meaningful or purely noise.

3. **Mismatch between outcome timing and instrument.** Oxycodone supply is measured 2006–2012, and MAT claims are from 2018–2024, but the paper interprets the IV as capturing a “supply-to-treatment pipeline elasticity” that persists for over a decade. This stretch relies on strong assumptions about the persistence of addiction stocks and treatment demand, yet the empirical specification is static cross-sectional. The paper should either provide justification (e.g., earlier Medicaid data, treatment rates over time) or, ideally, test whether the effect decays with longer lags (e.g., using earlier treatment years if available) before claiming this long-lasting “fiscal shadow.”

---

**Suggestions**

1. **Strengthen the empirical strategy via panel- or cohort-based checks.** While the main analysis is cross-sectional due to data constraints, you could explore whether earlier Medicaid treatment data (perhaps T-MSIS from 2014–2017 if available) show similar patterns, which would help validate the proposed lag structure. Alternatively, consider constructing placebo outcomes from other time periods (e.g., MAT claims in 2010–2014) or other populations (e.g., Medicaid spending for unrelated conditions) to show that the effect is specific to later opioid-related treatment demand.

2. **Explore heterogeneity and mechanism more fully.** The discussion hints that treatment response occurs primarily on the extensive margin. You could make this more concrete by decomposing claims into new versus continuing patients (if possible) or by showing how the effect varies with Medicaid expansion, opioid litigation settlements, or regional overdose rates. Such heterogeneity would bolster the argument that the instrument captures increased addiction incidence rather than policy-driven treatment supply.

3. **Provide richer discussion or evidence on the timing of triplicate program replacement.** The paper assumes that the initial supply shock via OxyContin marketing persisted despite later PDMPs. It would help to document when each triplicate state transitioned to newer monitoring systems and whether that transition co-varies with MAT outcomes. If some triplicate states abolished their programs earlier or later, you could use that variation to test whether the “shadow” wanes over time or persists, strengthening the credibility of the mechanism.

4. **Clarify the interpretation of the placebo test.** The precise null on non-opioid SUD treatment is compelling, but it would be useful to show whether baseline levels of non-opioid treatment differ systematically by triplicate status. If they do, it might indicate that the null result is driven by low statistical power in those outcomes; if they don’t, the null is more convincing. Presenting summary statistics for the placebo outcomes or even event-study-type evidence (if monthly data can be aggregated) would add confidence.

5. **Address potential measurement error in the treatment variable.** ARCOS records shipments, not prescriptions or actual consumption. If triplicate states had systematically different rates of pill diversion or retail pharmacist denial (e.g., more cautious dispensing), the instrument might be affecting the treatment variable differently than assumed. Some sensitivity analysis, such as replacing oxycodone pills with hydrocodone or total opioid shipments, could show that the estimated elasticity is not driven purely by measurement nuances.

6. **Improve inference reporting.** Because the IV is imprecise, reporting confidence intervals alongside point estimates (for both the main regressions and the placebo) would help readers assess statistical significance. Additionally, including the standard deviation of the endogenous variable and discussing what a “one-standard-deviation increase” corresponds to in raw pills or percent change would make the economic interpretation clearer.

7. **Consider alternative instruments or overidentification tests if possible.** While the triplicate program is the natural strategy, single instrument cross-sectional IVs are inherently limited. If other historical monitoring policies (e.g., B/S lists, early PDMP adoption) can plausibly serve as instruments or if you can interact the triplicate indicator with measures of Purdue marketing intensity, you could create overidentification tests or stronger first-stage variation.

8. **Expand on the policy implications carefully.** The concluding paragraphs suggest that opioid litigation settlements can rely on this supply-to-treatment pipeline. Given the imprecision, it may be more appropriate to frame this as suggestive evidence rather than a definitive elasticity. Discussing how litigation would use such elasticities (e.g., bounding estimates, combining with other data) would make the contribution more actionable.

Overall, this paper tackles an important question with a creative use of new data. With additional robustness checks, a clearer articulation of the timing assumptions, and more detailed inference reporting, the manuscript could make a solid contribution to the opioid economics literature.
